Atopic dermatitis (AD) is an increasingly common disease of uncertain etiology. Whereas much prior work has focused on an immunologic etiopathogenesis, recent linkage studies show that inherited mutations in a stratum corneum (SC) structural protein, filaggrin (FLG) occur in up to 30 percent of AD patients of European origin. In addition, several AD kindreds have now been described with putative gain-of-function polymorphisms in SC chymotryptic enzyme Kallikrein 7 (Klk7) and loss-of-function mutations in SPINK5, which encodes a key epidermal serine protease (SP) inhibitor, lymphoepithelial Kazal-type trypsin inhibitor (LEKTI). Together, these studies suggest that a primary abnormality in SC structure and function allows antigen access, thereby driving downstream immunologic phenomena in AD. Yet single-allele and even double-allele FLG mutations may only produce a milder, scaling disorder, ichthyosis vulgaris (IV). Our first hypothesis, therefore, is that more than one mutation may be required to transform IV into AD, and additive mutations that effect barrier function could predict convergent or divergent pathophysiological mechanisms. Yet, mutations alone may not suffice to produce AD, but superimposition of exogenous stressors, such as a decreased relative humidity (RH), repeated use of high pH surfactants, and/or sustained psychological stress (PS), could aggravate inherited structural/enzyme defects. All of these stressors are known to both disturb barrier function in normal skin, and to trigger or exacerbate AD. Their role in AD provocation will be assessed in two animal models of AD with defined, underlying SC defects. Then, we will assess the pathophysiological mechanisms leading to AD in fully genotyped humans with IV and AD, with FLG-/- plus one or more of the protease/antiprotease mutations. Further mechanistic studies will then be assessed in the animal models, including particularly the role of additive increases in pH provoking elevations in SP, with divergent, downstream pathways leading to barrier dysfunction, abnormal SC integrity, and primary cytokine release. Finally, based upon the dominant, operative pathophysiological mechanism, we will assess the potential utility of systemic and/or topical therapies that specifically target these pathomechanisms.

Public Health Relevance

. Atopic Dermatitis (AD) is an increasingly common inflammatory skin condition, predominantly affecting infants and children but its prevalence in adults is also increasing. AD not only places an enormous economic burden, but it also exacts an often-devastating toll on the quality of life of patients and families. We will be addressing the pathogenic role of inherited and acquired factors that could converge to degrade barrier function, allowing uptake of allergens leading to disease provocation. Because the current standard treatment of AD with glucocorticoids and calcineurin inhibitors is accompanied by significant side effects, alternate approaches, based upon correcting the primary barrier abnormality, could provide safer therapeutic alternatives. Because AD frequently represents the first step in the `atopic march,'which denotes the tendency to progress from initial AD in infants to include asthma and/or allergic rhinitis, therapy that corrects barrier function could also reduce the likelihood and/or severity of the `atopic march.'

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR019098-36
Application #
8242823
Study Section
Arthritis, Connective Tissue and Skin Study Section (ACTS)
Program Officer
Cibotti, Ricardo
Project Start
1979-04-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2014-03-31
Support Year
36
Fiscal Year
2012
Total Cost
$329,523
Indirect Cost
$120,435
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Man, George; Mauro, Theodora M; Zhai, Yongjiao et al. (2015) Topical hesperidin enhances epidermal function in an aged murine model. J Invest Dermatol 135:1184-7
Xin, Shujun; Mauro, Jacqueline A; Mauro, Theodora M et al. (2014) Ten-year publication trends in dermatology in mainland China. Int J Dermatol 53:e438-42
Elias, Peter M; Gruber, Robert; Crumrine, Debra et al. (2014) Formation and functions of the corneocyte lipid envelope (CLE). Biochim Biophys Acta 1841:314-8
Elias, Peter M (2014) Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta 1841:323-30
Man, Mao-Qiang; Lin, Tzu-Kai; Santiago, Juan L et al. (2014) Basis for enhanced barrier function of pigmented skin. J Invest Dermatol 134:2399-407
Elias, Peter M; Wakefield, Joan S (2014) Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 134:781-791.e1
Ye, Li; Lv, Chengzhi; Man, George et al. (2014) Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol 134:2843-6
Lin, Tzu-Kai; Man, Mao-Qiang; Santiago, Juan-Luis et al. (2014) Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated. J Invest Dermatol 134:2890-7
Hou, Maihua; Sun, Richard; Hupe, Melanie et al. (2013) Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms. Exp Dermatol 22:210-5
Lin, Tzu-Kai; Man, Mao-Qiang; Santiago, Juan-Luis et al. (2013) Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J Invest Dermatol 133:469-78

Showing the most recent 10 out of 187 publications